Timothy Ley

​​Timothy J. Ley, MD, a leukemia researcher and hematologist at the School of Medicine, has received a seven-year, $6.4 million Outstanding Investigator Award from the National Cancer Institute (NCI) of the National Institutes of Health (NIH). The funding will allow him to continue research aimed at understanding the mutations that initiate acute myeloid leukemia (AML), and how they might be targeted with new approaches.

​​Three scientists at Washington University School of Medicine in St. Louis and Siteman Cancer Center each will receive $900,000 in funding – $2.7 million total – over two years for their innovative approaches to fighting leukemia and other types of cancer.

For patients with an often-deadly form of leukemia, new research by Timothy J. Ley, MD, and colleagues suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.

​President Barack Obama has named internationally recognized cancer expert Timothy Ley, MD, of Washington University School of Medicine in St. Louis, to the National Cancer Advisory Board.

At least 2 percent of people over age 40 and 5 percent of people over 70 have mutations linked to leukemia and lymphoma in their blood cells, according to new research led by Li Ding, PhD, at the School of Medicine.

U.S. Sen. Roy Blunt (left) and Francis S. Collins, director of the National Institutes of Health, visited the School of Medicine this week to talk to researchers, administrators and entrepreneurs about scientific research and the need to boost and sustain federal funding for it.

The National Cancer Institute has awarded two major grants totaling $26 million to leukemia researchers and physicians at the School of Medicine. The funding has the potential to lead to novel therapies for leukemia that improve survival and reduce treatment-related side effects. Pictured are cancer cells from a patient with acute myeloid leukemia.

A consortium of researchers led by the School of Medicine has identified virtually all of the major mutations that drive acute myeloid leukemia (AML), a fast-growing blood cancer in adults that often is difficult to treat. The dark lines in the image pictured show all of the major mutations for AML that occurred in one patient with the disease.

Hundreds of mutations exist in leukemia cells at the time of diagnosis but nearly all occur randomly as a part of normal aging and are not related to cancer, new research at Washington University School of Medicine shows.